Try our Advanced Search for more refined results

In Re: Opana ER Antitrust Litigation

  1. December 16, 2022

    Opana End-Payors Get Final OK Of $15M Impax Deal

    After nearly a decade of litigation, an Illinois federal judge has signed off on a $15 million settlement ending indirect purchasers' claims that they overpaid for the prescription painkiller Opana ER due to a pay-for-delay deal struck between Endo Pharmaceuticals and Impax.

  2. November 04, 2022

    Opana Buyers' $145M Deal With $50M In Atty Fees Gets Final OK

    The attorneys who secured a $145 million settlement for direct purchasers of Endo Pharmaceuticals's Opana ER who said they overpaid generic-drug maker Impax Labs for the prescription painkiller because of a pay-for-delay deal will walk away from the litigation with more than $50 million for their trouble.

  3. September 20, 2022

    Opana Direct Buyers' Attys Seek $50M Fees After $145M Deal

    Attorneys for direct purchasers of Opana ER, including Value Drug Co. and Meijer Inc., asked an Illinois federal judge Monday for a fee award of $50 million after the class reached a $145 million settlement with generic-drug maker Impax Labs to end nearly eight years of litigation over pay-for-delay allegations.

  4. July 20, 2022

    Impax Inks $145M Deal With Direct Purchasers In Opana MDL

    Direct purchasers of Opana ER including Value Drug Co. and Meijer Inc. told an Illinois federal judge Tuesday they had reached a $145 million settlement with generic-drug maker Impax Labs to end nearly eight years of "intense" litigation over pay-for-delay allegations that Endo Pharmaceuticals beat at trial.

  5. July 01, 2022

    Jury Hands Endo Win In Opana Pay-For-Delay Case

    An Illinois jury sided with Endo Pharmaceuticals on Friday over allegations that it struck an unlawful settlement with Impax Laboratories to delay a generic version of Endo's Opana ER painkiller, finding the deal did more to boost competition than stifle it. 

  6. June 30, 2022

    Endo 'Made Out Like A Bandit' With Opana Deal, Buyers Say

    Opana ER buyers told an Illinois federal jury Thursday that Endo Pharmaceuticals raked in profits by striking an unlawful settlement to delay a generic competitor for its opioid, saying the deal forced them to pay higher prices longer than they should have.

  7. June 24, 2022

    Retailers Cut Midtrial Deal With Impax In Opana Delay Case

    Well into an antitrust trial over an alleged pay-for-delay scheme surrounding Endo Pharmaceuticals' Opana ER painkiller, a group of major retail chains cut a midtrial settlement Friday with Impax Laboratories, one of the defendants in the wide-ranging case.

  8. June 14, 2022

    Impax Got Earliest Possible Generic Opana Entry, Jury Hears

    In an ongoing antitrust trial over an alleged pay-for-delay scheme surrounding Endo Pharmaceuticals' Opana ER painkiller, a former Impax Laboratories executive testified Tuesday that the generic-drug maker had always pushed to bring its version to market as soon as possible.

  9. February 28, 2022

    Opana Buyers Want Pay-For-Delay Trial Split In 3

    Buyers who say they overpaid for the prescription painkiller Opana ER want their pay-for-delay fight with Endo Pharmaceuticals and Impax Laboratories sliced into three separate trials, the buyers told an Illinois federal court Friday.

  10. July 14, 2021

    7th Circ. Orders Judge Consider Copay Groups In Opana Cert.

    A Seventh Circuit panel on Tuesday sent a class certification decision back for partial reconsideration because an Illinois federal judge didn't analyze the potential for uninjured members winding up in the class of Opana ER end-payors accusing Endo Pharmaceuticals of cutting an anti-competitive pay-for-delay deal protecting the painkiller.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!